AU2021239631B2 - Oxadiazole derivative - Google Patents
Oxadiazole derivativeInfo
- Publication number
- AU2021239631B2 AU2021239631B2 AU2021239631A AU2021239631A AU2021239631B2 AU 2021239631 B2 AU2021239631 B2 AU 2021239631B2 AU 2021239631 A AU2021239631 A AU 2021239631A AU 2021239631 A AU2021239631 A AU 2021239631A AU 2021239631 B2 AU2021239631 B2 AU 2021239631B2
- Authority
- AU
- Australia
- Prior art keywords
- oxadiazol
- compound
- substituted
- alkyl
- fluorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046138 | 2020-03-17 | ||
| JP2020-046138 | 2020-03-17 | ||
| PCT/JP2021/010628 WO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | オキサジアゾール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2021239631A1 AU2021239631A1 (en) | 2022-11-10 |
| AU2021239631A8 AU2021239631A8 (en) | 2022-12-01 |
| AU2021239631B2 true AU2021239631B2 (en) | 2026-05-14 |
Family
ID=77768228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021239631A Active AU2021239631B2 (en) | 2020-03-17 | 2021-03-16 | Oxadiazole derivative |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12624011B2 (en) * | 2020-03-17 | 2026-05-12 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
| JP7653399B2 (ja) | 2021-09-22 | 2025-03-28 | 住友ファーマ株式会社 | オキサジアゾール誘導体を含有する医薬組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017075312A1 (en) * | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1227978A (cg-RX-API-DMAC7.html) * | 1968-09-13 | 1971-04-15 | ||
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| RU2426731C2 (ru) * | 2005-12-23 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | Производные арил-изоксазоло-4-ил-оксадиазола |
| RU2009127095A (ru) * | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| GB0723814D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| JP5746612B2 (ja) * | 2008-03-19 | 2015-07-08 | オーリムメッド・ファルマ・インコーポレーテッド | 中枢神経系疾患および障害の治療に有効な新規化合物 |
| WO2010017132A1 (en) * | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US20110224304A1 (en) * | 2008-11-14 | 2011-09-15 | Dainippon Sumitomo Pharma Co., Ltd. | Biphenylacetamide derivative |
| JP2012001537A (ja) * | 2010-05-19 | 2012-01-05 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体からなる医薬 |
| WO2011145669A1 (ja) * | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| SI2772482T1 (sl) * | 2011-10-27 | 2016-06-30 | Taisho Pharmaceutical Co., Ltd. | Derivat azola |
| JP2013221025A (ja) * | 2012-04-19 | 2013-10-28 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体の製造方法及びその中間体 |
| WO2014072957A1 (en) * | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US12624011B2 (en) * | 2020-03-17 | 2026-05-12 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
-
2021
- 2021-03-16 US US17/905,847 patent/US12624011B2/en active Active
- 2021-03-16 CN CN202180036916.0A patent/CN115515943B/zh active Active
- 2021-03-16 ES ES21770862T patent/ES3041051T3/es active Active
- 2021-03-16 JP JP2022508381A patent/JP7637121B2/ja active Active
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja not_active Ceased
- 2021-03-16 AU AU2021239631A patent/AU2021239631B2/en active Active
- 2021-03-16 PT PT217708627T patent/PT4122923T/pt unknown
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
- 2021-03-16 EP EP21770862.7A patent/EP4122923B1/en active Active
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 TW TW110109295A patent/TWI879917B/zh active
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko active Pending
- 2021-03-16 PH PH1/2022/552373A patent/PH12022552373A1/en unknown
- 2021-03-16 FI FIEP21770862.7T patent/FI4122923T3/fi active
- 2021-03-16 DK DK21770862.7T patent/DK4122923T3/da active
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
-
2025
- 2025-02-14 JP JP2025022409A patent/JP2025081449A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017075312A1 (en) * | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
Also Published As
| Publication number | Publication date |
|---|---|
| US12624011B2 (en) | 2026-05-12 |
| US20230092498A1 (en) | 2023-03-23 |
| US20230265061A1 (en) | 2023-08-24 |
| TWI879917B (zh) | 2025-04-11 |
| ES3041051T3 (en) | 2025-11-06 |
| FI4122923T3 (fi) | 2025-11-12 |
| EP4122923A4 (en) | 2024-04-24 |
| KR20220154208A (ko) | 2022-11-21 |
| DK4122923T3 (da) | 2025-12-15 |
| CA3170273A1 (en) | 2021-09-23 |
| AU2021239631A8 (en) | 2022-12-01 |
| TW202146392A (zh) | 2021-12-16 |
| JP2025081449A (ja) | 2025-05-27 |
| WO2021187486A1 (ja) | 2021-09-23 |
| CN115515943B (zh) | 2024-07-09 |
| PH12022552373A1 (en) | 2023-12-18 |
| PT4122923T (pt) | 2025-12-03 |
| JP7637121B2 (ja) | 2025-02-27 |
| BR112022017530A2 (pt) | 2022-10-18 |
| EP4122923B1 (en) | 2025-09-10 |
| CN115515943A (zh) | 2022-12-23 |
| EP4122923A1 (en) | 2023-01-25 |
| JPWO2021187486A1 (cg-RX-API-DMAC7.html) | 2021-09-23 |
| AU2021239631A1 (en) | 2022-11-10 |
| US11718592B2 (en) | 2023-08-08 |
| MX2022011483A (es) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU758807B2 (en) | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists | |
| KR100896838B1 (ko) | 모폴린 화합물 | |
| KR20160138289A (ko) | 항섬유성 피리디논 | |
| HUE025313T2 (en) | Piperidine and piperazine-1-carboxylic acid amide derivatives and related compounds as Fatty Acid Hydrolase (FAAH) modulators for the treatment of anxiety, pain and other conditions | |
| JP2016510032A (ja) | 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体 | |
| KR20150064746A (ko) | 항섬유성 피리디논 | |
| KR20200139702A (ko) | 칼페인 조정자 및 그 치료학적 용도 | |
| JP2004528375A (ja) | 新規ピリジノンおよび関連の複素環誘導体 | |
| JP2025081449A (ja) | オキサジアゾール誘導体 | |
| JP2021500334A (ja) | Ehmt2阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 | |
| JP2026083313A (ja) | テトラヒドロキノリン誘導体及びその医薬用途 | |
| MX2007015678A (es) | Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a. | |
| US20050282811A1 (en) | Diazabicyclic histamine-3 receptor antagonists | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| WO2016006593A1 (ja) | 新規ベンズオキサジン誘導体及びこれを含有する医薬 | |
| HK40086571A (en) | Oxadiazole derivative | |
| HK40086571B (en) | Oxadiazole derivative | |
| EA048061B1 (ru) | Производное оксадиазола | |
| JP7653399B2 (ja) | オキサジアゾール誘導体を含有する医薬組成物 | |
| EP1908752A1 (en) | Novel 2-quinolone derivative | |
| RU2850795C1 (ru) | Производное тетрагидрохинолина и его медицинское применение | |
| US20070270436A1 (en) | Novel amino- and imino-alkylpiperazines | |
| CN104000817B (zh) | 一类含1,3,4-噁二唑啉的吡唑衍生物在制备治疗、防肿瘤疾病药物中的用途 | |
| CN119707941A (zh) | 一类喹啉酮化合物、其制备方法和用途 | |
| JP2023045508A (ja) | イソオキサゾリン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 36 , NO 45 , PAGE(S) 6211 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SUMITOMO DAINIPPON PHARMA CO., LTD., APPLICATION NO. 2021239631, UNDER INID (71) CORRECT THE APPLICANT NAME TO SUMITOMO PHARMA CO., LTD. |